Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection recommend a combination antiretroviral regimen composed of two nucleoside reverse transcriptase inhibitors plus a ritonavir boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor.

The non-nucleoside reverse transcriptase inhibitors licensed for naïve patients - nevirapine and efavirenz - have both been asociated with increased rates of hepatotoxicity (nevirapine) and CNS toxicity (efavirenz) in HIV/HCV co-infected patients. Although PI-based therapy has dramatically reduced morbidity and mortality, it has been limited by complex dosing regimens and toxicities, leading to adherence challenges. Varying degree of liver insufficiency may necessitate pharmacokinetic monitoring of the protease inhibitor and may necessitate dose adjustments. In HIV/HCV co-infected patients HAART based on another class of antiretrovirals than NNRTI or PI may thus offer advantages with regard to adverse events and thus long-term efficacy.

The overall intention of this trial is to examine in a non-inferiority design the safety and efficacy of a raltegravir based HAART with a standard-of-care HAART in HIV-/HCV co-infected patients. The standard of care used in this study will be atazanavir/ritonavir. All patients will in addition receive a fixed combination of tenofovir and emtricitabine.

The primary end-point is the rate of hepatotoxic events, defined by ALT elevations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970

HIV Infections

TERMINATED PHASE4

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227

HIV, Combination Therapy

COMPLETED PHASE4

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879

Acquired Immune Deficiency Syndrome AIDS Human Immunodeficiency Virus +1 more

COMPLETED NA

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

NCT01105611

HIV Infections Hepatitis C

UNKNOWN PHASE4

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147

HIV Infections

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Raltegravir

45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine

Group Type EXPERIMENTAL

raltegravir

Intervention Type DRUG

Patients will be randomized 1:1 to either the experimental or the active control arm

Atazanavir/ritonavir

45 patients will receive open label atazanavir/ritonavir

Group Type ACTIVE_COMPARATOR

Atazanavir/ritonavir

Intervention Type DRUG

Patients will be randomized 1:1 to either the experimental or the active control arm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

raltegravir

Patients will be randomized 1:1 to either the experimental or the active control arm

Intervention Type DRUG

Atazanavir/ritonavir

Patients will be randomized 1:1 to either the experimental or the active control arm

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV and Hepatitis C co-infected patients
* indication for HAART according to current German-Austrian guidelines
* HAART naive
* no primary NRTI / Integrase / PI associated resistance mutation according to the Stanford algorithm at screening; every patient MUST have a genotypic resistance assay prior baseline available (\< 6 months prior to baseline)
* women of childbearing age: negative pregnancy test
* ability to sign written informed consent

Exclusion Criteria

* advanced liver cirrhosis Child-Pugh B or C or decompensated liver disease
* Pegylated interferon / ribavirin or other anti-HCV therapy; planned anti-HCV therapy for duration of the study (48 weeks).
* acute or chronic hepatitis B infection
* acute hepatitis A or other hepatotropic virus infections
* any other chronic liver disease such as alcohol abuse or hemosiderosis
* use or planned use (for the duration of the study, 48 weeks) of rifampicin, St. John´s wort and drugs that are metabolized via the cytochrome P450 system with a narrow therapeutic PK-range such as astemizole, terfenadine, cisapride, pimozide, chinidin, bepridil, triazolam, midazolam, ergotamine, dihydroergotamin, ergometrine, methyl-ergometrine. FOR OTHER COMEDICATIONS please consult with the SPC of Raltegravir (Isentress®), Atazanavir (Reyataz®), Ritonavir (Norvir®), your hospital pharmacist, www.hiv-drug-interactions.org or the principal investigator in case of uncertainty.
* new AIDS defining event, except for Kaposi sarcoma, \< 1 months prior to screening
* malignancy, except for Kaposi sarcoma, with current radio- or chemotherapy
* history of organ transplantation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No